Loading organizations...
§ Private Profile · South San Francisco, CA, USA
Biopharmaceutical company developing cancer treatments for immuno-oncology, using Probodies activated in tumor microenvironment.
CytomX Therapeutics has raised $131.0M across 4 funding rounds.
Key people at CytomX Therapeutics.
CytomX Therapeutics has raised $131.0M in total across 4 funding rounds.
CytomX Therapeutics is a South San Francisco, California-based biotechnology company that develops targeted cancer treatments using its proprietary Probody platform to create masked antibodies that activate selectively within the tumor microenvironment. Operating as a publicly traded entity on the NASDAQ, the firm transitioned to the public markets in 2015, roughly 5 years after securing its initial venture capital financing led by Third Rock Ventures. The organization generates revenue primarily through strategic research and development partnerships, collaborating with major pharmaceutical corporations such as Bristol-Myers Squibb, AbbVie, Pfizer, and Amgen. These alliances have driven significant market events, including a 35 percent stock price increase in October 2017 following the announcement of its co-development agreement with Amgen. Originating from research conducted at the University of California, Santa Barbara, CytomX Therapeutics was founded in 2008 by Patrick Baeuerle.
CytomX Therapeutics has raised $131.0M across 4 funding rounds. Most recently, it raised $70.0M Series D in June 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 17, 2015 | $70M Series D | Fidelity Management & Research Company | Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Capital Management, Venrock, Wellington Management | Announced |
| Jan 1, 2015 | $20M Series C | — | Canaan Partners, Pivotal BioVenture Partners, SV Health Investors, Third Rock Ventures, Canaan Partners, Roche | Announced |
| Jul 1, 2012 | $11M Series B | TIM Shannon | Canaan Partners, Pivotal BioVenture Partners, SV Health Investors, Third Rock Ventures, Roche | Announced |
| Sep 1, 2010 | $30M Series B | Third Rock Ventures | SV Health Investors, Roche | Announced |
CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing Probody® therapeutics, which are conditionally activated biologics designed to localize activation in the tumor microenvironment for enhanced safety and efficacy in cancer treatment.[1][2] The company builds novel antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and cytokines like CX-2051 (anti-EpCAM ADC for epithelial cancers such as colorectal), CX-801 (IFN alpha-2b for melanoma and other tumors), CX-904 (EGFR/CD3 bispecific), and others in its pipeline, serving patients with advanced solid tumors and partnering with firms like Amgen, Bristol Myers Squibb, Regeneron, Moderna, and Merck.[1][3] It solves the problem of potent anti-cancer agents' toxicity to healthy tissues by masking them until they reach tumors, opening therapeutic windows for previously undruggable targets; with 121 employees and multiple Phase 1 trials ongoing, growth momentum includes initial data readouts for CX-2051 in H1 2025 and CX-801 in H2 2025.[1][3]
Founded in 2008 in South San Francisco, California, CytomX emerged from pioneering research into conditional activation technologies to address limitations in oncology biologics, leveraging the Probody platform for tumor-specific drug activation.[1][2] Key scientific leaders include experts like those from Genentech/Roche (e.g., developers of ADCs like polatuzumab vedotin and bispecifics like mosunetuzumab), ImmunoGen (ADC innovator behind Kadcyla®), and academic researchers in tumor immunology and immunotherapy, though specific founders are not detailed in available profiles.[4] Early traction built through strategic collaborations with major biopharma (Amgen, Astellas, BMS, Regeneron, Moderna) and its 2015 IPO, evolving from preclinical validation to a deep clinical pipeline advancing best-in-class and first-in-class therapies.[1][3]
CytomX rides the explosive growth in precision oncology, particularly ADCs and bispecifics, where the market is projected to expand amid demands for safer, tumor-selective therapies amid rising cancer incidence.[1][3] Timing is ideal post-2020s immuno-oncology boom, as limitations of systemic toxins (e.g., narrow windows for cytokines or EpCAM) create opportunities for conditional activation to complement checkpoints like PD-1 and next-gen modalities.[2][3] Market forces favoring it include biopharma's push for differentiated assets via partnerships and the shift toward "cold" tumor activation in immuno-resistant cancers; CytomX influences the ecosystem by licensing its platform, co-developing with giants, and pioneering Probody tech that could redefine biologic safety profiles.[1][4]
CytomX is poised for inflection with 2025 Phase 1 data readouts from CX-2051 and CX-801, potentially validating the Probody platform and unlocking partnerships or advancement to later stages.[3] Trends like ADC dominance, bispecific expansion, and combo immuno-therapies will shape its path, with success hinging on biomarker data demonstrating superior indices over standards.[3] Influence may evolve toward platform leadership if readouts succeed, expanding beyond oncology or amplifying via more big-pharma deals, ultimately revolutionizing cancer care by safely unleashing potent biologics—as a different kind of biopharma intent on destroying cancer, differently.[2]
Key people at CytomX Therapeutics.
CytomX Therapeutics has raised $131.0M in total across 4 funding rounds.
CytomX Therapeutics's investors include Fidelity Management & Research Company, Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Capital Management, Venrock, Wellington Management, Canaan Partners, Pivotal bioVenture Partners, SV Health Investors.
